Lafene

Fentanyl, the active ingredient in Lafene, is an opioid analgesic presented as a transdermal patch for transdermal use. It provides continuous systemic delivery to manage severe chronic pain, cancer‑related pain, and other conditions that require ongoing opioid therapy in adult patients.

GNH USA supplies Lafene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with rigorous quality assurance and regulatory compliance.

Lafene (fentanyl) is indicated for conditions requiring potent, continuous opioid analgesia.

- Severe chronic pain: provides long‑acting relief for patients with persistent severe pain not adequately controlled by other analgesics. - Cancer‑related pain: delivers steady opioid levels to manage moderate to severe pain associated with malignant disease. - Pain requiring continuous opioid therapy: offers a non‑oral route for patients who need around‑the‑clock opioid coverage.

Lafene may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Constipation: reduced bowel movements. - Drowsiness: increased sleepiness or fatigue. - Skin irritation at patch site: redness, itching, or rash.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Opioid dependence or withdrawal: signs of addiction or withdrawal on discontinuation.

When prescribing Lafene, clinicians should observe several safety precautions to minimize risks.

- Patient selection: assess opioid tolerance and risk of respiratory depression before initiating therapy. - Dose titration: start with the lowest effective dose and adjust cautiously under medical supervision. - Concomitant CNS depressants: avoid or closely monitor use with benzodiazepines, alcohol, or other sedatives. - Pregnancy and lactation: use only if benefits outweigh potential fetal or neonatal risks. - Monitoring: regularly evaluate pain control, signs of overdose, and skin condition at the patch site. - Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Lafene can interact with other medicines, altering its analgesic effect or increasing adverse events.

Major Interactions (Avoid): - Respiratory depressants: concurrent use with benzodiazepines or barbiturates may cause profound respiratory depression. - CYP3A4 inhibitors: strong inhibitors such as ketoconazole or clarithromycin can raise fentanyl plasma levels, increasing toxicity risk. - MAO inhibitors: combined use may precipitate severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: agents like rifampin may reduce fentanyl concentrations, diminishing analgesia. - CNS stimulants: drugs that counteract sedation (e.g., stimulants) may mask opioid effects. - Alcohol: moderate to heavy intake can enhance central nervous system depression.